PDCD1 and lymphoma: Knockdown with siRNAs or the inhibition of GSK-3 by the SMI SB415286 in CD8+ CTL reduced the cell surface expression of PD-1 and increased their cytolytic activity against a lymphoma cell line in vitro as well as viral clearance [100].